The ELEGANT Study is testing elacestrant to see if it could help people with early-stage breast cancer that could recur. Elacestrant will be compared with the endocrine therapy you usually take for your node-positive, ER-positive, HER2-negative early-stage breast cancer.
The ELEGANT Study could last up to 8 years, including:
- 4-week screening period: you will have tests at your nearest study center to see if you can take part.
- 5-year study treatment period: if eligible, you will take the investigational drug or endocrine therapy and visit the study center for further tests.
- Safety follow-up: 4 weeks after your last dose of study treatment, you will return to the study center for final tests.
- Long-term follow-up: the study team will contact you every year for about 5 years to check on your health.
You will have a 50% (1 in 2) chance of receiving the investigational drug elacestrant and a 50% chance of continuing to take endocrine therapy that is considered standard of care. You cannot choose but you will know what you are receiving.
Elacestrant and endocrine therapy come in tablet/pill form, which you will be asked to take every day for 5 years.
During the study treatment period, you will visit the study center for tests approximately 12 times over 5 years.